Glaucoma, diabetic retinopathy, and other serious eye diseases associated with aging are a major risk factor for the vision loss and blindness. By exploiting our understanding of the mechanisms of cell death during these diseases, we can contribute to the need to reduce healthcare costs and reduce the burden that blindness can place on our society.
Current estimates suggest a global glaucoma prevalence of over 60 million cases. And, with an aging population, this prevalence is growing rapidly. Most cases are associated with elevated intraocular pressure. However, despite the availability of drugs which reduce intraocular pressure, visual impairment and vision loss remain a problem. While most cases are associated with elevated intraocular pressure, approximately 25% of cases have normal intraocular pressure. Patients are frequently treated with drugs
At Connexin Therapeutics, we are developing the options ophthalmologists need to preserve vision in their patients with glaucoma and related conditions.